Xenon Pharmaceuticals Inc. Common Shares (XENE)
NASDAQ: XENE · Pharmaceutical Preparations · Burnaby,
Our rating: Neutral
Call changed from Cautious to Neutral at $41.39, moderate conviction, November 10, 2026.
Breaks if: The Neutral call breaks toward Cautious if annual FCF burn accelerates beyond $380M across the next four reported quarters or a lead clinical program misses its primary endpoint in the next 12 months. It breaks toward Positive if Xenon secures a Phase 3 success or receives an FDA approval — or a confirmed PDUFA date — that converts pipeline probability into near-certain commercial revenue within the same 12-month window.
Key figures
| Market value | $3.6B |
|---|---|
| Revenue, last 12 months | $0.00 |
| Net income, last 12 months | −$429M |
| Free cash flow, last 12 months | −$357M |
| Price to earnings | n/a |
| Free cash flow yield | −9.8% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −50.3% |
| Beta to the S&P 500 | 0.88 |
| Volatility, annualized | 53.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $0.00 | n/a | $-1.11 | −$91M |
| June 30, 2026 | $0.00 | n/a | $-1.11 | −$96M |
| March 31, 2026 | $0.00 | −100.0% | $-1.17 | −$89M |
| December 31, 2025 | $0.00 | n/a | $-1.31 | −$82M |
| September 30, 2025 | $0.00 | n/a | $-1.15 | −$72M |
| June 30, 2025 | $0.00 | n/a | $-1.07 | −$64M |
| March 31, 2025 | $8M | n/a | $-0.83 | −$62M |
| December 31, 2024 | $0.00 | n/a | $-0.84 | −$55M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 3%, Gemini 2%, Mistral 3%
- Free cash flow for the quarter is above zero: Claude 4%, Gemini 2%, Mistral 2%
14 ledger entries and 50 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.